Quince Therapeutics Inc
For the period ended Mar 31, 2024. Filed May 13, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 13, 2024
QNCX$31.73+8.1%Stored close · as of Oct 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Loss
(In thousands, except share and per share amounts)
| Three Months Ended March 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Operating expenses: | ||
| Research and development | $3,702 | $3,230 |
| General and administrative | 4,971 | 3,826 |
| Intangible asset impairment charge | — | 5,900 |
| Fair value adjustment for contingent consideration | 2,545 | — |
| Total operating expenses | 11,218 | 12,956 |
| Loss from operations | (11,218) | (12,956) |
| Fair value adjustment for long-term debt | (388) | — |
| Interest income | 887 | 700 |
| Other expense, net | (399) | (246) |
| Net loss before income tax benefit | (11,118) | (12,502) |
| Income tax (expense) benefit | (31) | 248 |
| Net loss | (11,149) | (12,254) |
| Other comprehensive loss: | ||
| Foreign currency translation adjustments | (1,229) | 92 |
| Unrealized gain on available-for-sale securities | 7 | 235 |
| Total comprehensive loss | $(12,371) | $(11,927) |
| Net loss per share - basic and diluted | $(0.26) | $(0.34) |
| Weighted average shares of common stock outstanding - basic and diluted | 43,010,212 | 35,855,200 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.